Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808449 | 1.00 | MEN1 (0.35) | MEN1CYP1A2KMT2ACTDSP1SSTR4 | |
| SCHEMBL2806170 | 0.88 | CTDSP1 (0.35) | MEN1CYP1A2KMT2ACTDSP1POLB | |
| SCHEMBL186029 | 0.88 | CTDSP1 (0.33) | MEN1CYP1A2KMT2ACTDSP1SSTR4 | |
| SCHEMBL185594 | 0.88 | SMN1; SMN2 (0.38) | MEN1CYP1A2KMT2ACTDSP1SSTR4 | |
| SCHEMBL198810 | 0.88 | SMN1; SMN2 (0.38) | MEN1CYP1A2KMT2ACTDSP1SSTR4 | |
| SCHEMBL2804900 | 0.88 | SMN1; SMN2 (0.38) | MEN1CYP1A2KMT2ACTDSP1SSTR4 | |
| SCHEMBL13128471 | 0.87 | CTDSP1 (0.39) | CTDSP1POLBP2RX7NFKB1NFKB2 | |
| SCHEMBL13128461 | 0.86 | CTDSP1 (0.36) | CTDSP1POLBP2RX7NFKB1NFKB2 | |
| SCHEMBL2808619 | 0.85 | CTDSP1 (0.35) | MEN1CYP1A2KMT2ACTDSP1POLB | |
| SCHEMBL2807540 | 0.82 | POLB (0.36) | MEN1CYP1A2KMT2ACTDSP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2401256-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2013-04-17 | — | — | EP | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | MEN1 314/4885CYP1A2 892/4885KMT2A 4682/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | MEN1 314/4885CYP1A2 892/4885KMT2A 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.